Literature DB >> 7821478

Learning phacoemulsification: the surgeon-in-training.

H Tabandeh1, B Smeets, M Teimory, H Seward.   

Abstract

With the increasing trend towards phacoemulsification a perceived increased complication rate during the learning curve gives rise to a dilemma as to the best stage at which a surgeon-in-training can safely learn the technique. We prospectively analysed the complications and visual outcome of the first 160 phacoemulsification procedures performed by three surgeons-in-training. The main outcome measures included posterior capsule tear, vitreous and nuclear loss, surgical re-intervention rate and visual outcome. Posterior capsule tear occurred in 7 eyes (4.4%) and vitreous loss in 6 (3.8%). No nucleus was lost in the vitreous. Surgical re-intervention was required in 1 eye. Best corrected visual acuity was 6/12 or better in 88% of eyes. These results compare favourably with reports of surgeons-in-training learning extracapsular surgery and also with recently reported phacoemulsification series. This study indicates that with careful case selection and supervision phacoemulsification can be a safe procedure.

Entities:  

Mesh:

Year:  1994        PMID: 7821478     DOI: 10.1038/eye.1994.113

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  3 in total

1.  Visual outcome and complications after posterior capsule rupture during phacoemulsification surgery.

Authors:  E Y Yap; W J Heng
Journal:  Int Ophthalmol       Date:  1999       Impact factor: 2.031

2.  Validation of Najjar-Awwad cataract surgery risk score for resident phacoemulsification surgery.

Authors:  Preston H Blomquist; James W Sargent; Heather H Winslow
Journal:  J Cataract Refract Surg       Date:  2010-10       Impact factor: 3.351

3.  Phacoemulsification at King Khaled Eye Specialist Hospital--the experience of the past.

Authors:  K D Teichmann; A A al-Rajhi; M H Jabak; S R Antonios; S Haddab; S D Smith
Journal:  Int Ophthalmol       Date:  1997       Impact factor: 2.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.